公开(公告)号：EP3103813A1

公开(公告)日：2016-12-14

申请号：EP16161751.9

申请日：2008-12-08

申请人： ZymoGenetics, Inc.

发明人： JASPERS, Stephen R. ,  RIXON, Mark W. ,  DILLON, Stacey R. ,  RAMSDELL, Frederick J. ,  KREJSA, Cecile M. ,  YI, Eugene C.

IPC分类号： C07K16/24 ,  A61K39/395

CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  Y10S530/809

摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.

摘要翻译： 提出人抗人IL-21单克隆抗体和产生它们的杂交瘤。 这些抗体中的某些具有结合天然人IL-21，人IL-21的突变重组体IL-21蛋白和/或肽区的能力。 这些人抗IL-21抗体可用于治疗自身免疫性和炎性疾病，特别是由T滤泡辅助细胞，B细胞TH细胞或TH17细胞介导的疾病。

公开(公告)号：EP2274008B1

公开(公告)日：2014-02-26

申请号：EP09724060.0

申请日：2009-03-27

申请人： ZymoGenetics, Inc.

发明人： SIVAKUMAR, Pallavur V. ,  GILBERTSON, Debra G. ,  SNAVELY, Marshall D. ,  MABRY, George R. ,  YI, Eugene C. ,  YAO, Yue ,  PRESNELL, Scott R.

IPC分类号： A61K39/395 ,  A61P35/00 ,  C07K16/22 ,  C07K16/28

CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92

摘要： There is provided an isolated antibody that binds to the extracellular domain of PDGFR² and neutralizes PDGFR² activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein: LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443; LCDR2 has the amino acid sequence shown in SEQ ID NO: 434; LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444; HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445; HCDR2 has the amino acid sequence shown in SEQ ID NO: 437; HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442